Testing a new medicine for kidney damage in chronic kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 27 or higher.
- You have reduced kidney function (based on a blood test).
- You have protein in your urine (a sign of kidney damage).
- You are not pregnant, breastfeeding, or planning to become pregnant, or you are using highly effective birth control.
- You have not taken a GLP-1 receptor agonist (like Ozempic, Wegovy, or Mounjaro) in the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests HRS-7535, a new oral tablet that may help protect kidneys in people with chronic kidney disease. GLP-1 medications were originally developed for diabetes but may also benefit kidney function and overall health.
This study tests a new drug called IGT-303 for people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and can help protect kidney function.
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This study tests a new medicine called NNC0487-0111 to see how well it helps people with excess body weight and type 2 diabetes lose weight, compared to another medicine called semaglutide. It may be an option if you have type 2 diabetes and are looking to manage your weight.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.